About
Sten Verland is a venture partner and founding partner at Sunstone Life Science Ventures who brings experience in executive management, venture capital, and pharmaceutical development. He holds a PhD in Immunology and has served as a CEO, board member, and chairman across biotech and pharmaceutical companies, with expertise in drug development, M&A, and fundraising. Verland also participates in innovation funding committees supporting early-stage life science ventures.
Contact· self-published, not guessed
Experience
- Sunstone Life Science VenturesVenture Partner (founding partner)current2024 — presentCopenhagen Metropolitan Area
- Sunstone Life Science VenturesGeneral Partner (founding partner)2007 — 2024Copenhagen Metropolitan Area
- Verland - Life Science Venture & ConsultingCEO & Ownercurrent1994 — presentCopenhagen Metropolitan Area
- Minervax ApSNon Executive Directorcurrent2014 — presentCopenhagen Metropolitan Area
- Minervax ApSChair of the Audit Committeecurrent2020 — presentCopenhagen Metropolitan Area
- Sulis TherapeuticsChair of the Board of Directorscurrent2026 — presentAarhus, Central Denmark Region, Denmark
- Proxi BiotechChair of the Board of Directorscurrent2025 — presentCoopenhagen, Denmark
- Innovation Fund DenmarkMember of the InnoFounder selection committeecurrent2014 — presentCopenhagen Metropolitan Area
- Innovation Fund DenmarkMember of the InnoExplorer selection committee2019 — 2024Copenhagen Metropolitan Area
- Innovation Fund DenmarkMember of the InnoBooster selection committee2018 — 2021Copenhagen Metropolitan Area
- Skovlyst Production A/SNon Executive Directorcurrent2018 — presentCopenhagen Metropolitan Area
- Skovlyst Production A/SPrivate investor (through Verland Capital ApS)current2009 — presentCoopenhagen, Denmark
- The Research Council of NorwayPanel Member2020 — 2025Oslo, Norway
- Neumirna TherapeuticsChair of the Board of Directors2022 — 2025Copenhagen Metropolitan Area
- Anergis SANon Executive Director2011 — 2024Lausanne, Vaud, Switzerland
- Stipe TherapeuticsMember of the Audit Committee2019 — 2024Aarhus, Central Denmark Region, Denmark
- Stipe TherapeuticsNon Executive Director2019 — 2024Aarhus, Central Denmark Region, Denmark
- Vaximm AGBoard Observer2019 — 2022Basel, Switzerland
- Vaximm AGNon Executive Director2011 — 2019Basel, Switzerland
- OxTheraNon Executive Director2016 — 2022Greater Stockholm Metropolitan Area
- Orphazyme A/SMember of the Audit Committee2017 — 2021Copenhagen Metropolitan Area
- Orphazyme A/SMember of the Nomination Committee2017 — 2021Copenhagen Metropolitan Area
- Orphazyme A/SNon Executive Director2011 — 2021Copenhagen Metropolitan Area
- BioInnovation InstituteMember of the selection committee for the Creation House incubator2018 — 2020Copenhagen Metropolitan Area
- DVCA - Danish Venture Capital and Private Equity AssociationMember of the Board of Directors2012 — 2020Copenhagen Metropolitan Area
- DVCA - Danish Venture Capital and Private Equity AssociationMember of the Venture Capital Committee2012 — 2020Copenhagen Metropolitan Area
- Glycom A/SPrivate investor (through Verland Capital)2005 — 2020Copenhagen Metropolitan Area
- Glycom A/SNon Executive Director2005 — 2007Copenhagen Metropolitan Area
- F2G LTDNon Executive Director2010 — 2018Greater Manchester, England, United Kingdom
- Rigontec GmbHNon Executive Director2015 — 2017Cologne Bonn Region
- NsGene A/SNon Executive Director2014 — 2017Copenhagen Metropolitan Area
- ZymenexChair of the Board of Directors2010 — 2013Hillerød, Denmark
- ZymenexNon Executive Director2006 — 2010Hillerød, Denmark
- Action Pharma A/SChair of the Board of Directors2009 — 2012Aarhus, Central Denmark Region, Denmark
- Synarc (now Clario)VP General Manager Europe1999 — 2003Copenhagen Metropolitan Area & San Francisco Bay Area
- M&B A/S (now Taconic Biosciences)CEO & co-owner1993 — 1999Copenhagen Metropolitan Area
- Scanpharm A/SHead of R&D1990 — 1992Copenhagen Metropolitan Area
- Institute for Experimental Immunology, Medical School, University of CopenhagenAssistant Professor1989
- Department of Clinical Chemistry, Bispebjerg Hospital, CopenhagenSenior Research Scientist1988 — 1989
- Institute for Experimental Immunology, Medical School, University of CopenhagenResearch Scientist1986 — 1987
Skills & more
Venture Capital59Biotechnology45Entrepreneurship37Drug Development19Lifesciences19Mergers9Business Strategy12Immunology12Corporate Development9Mergers & Acquisitions8R&D6Clinical Development5
+12 more
StrategyExecutive ManagementPrivate EquityPharmaceutical IndustryAngel InvestingVenture FinancingClinical TrialsIPONegotiationAdvisory BoardsStart-upsCommercializationLanguages Danish · English · German · Other Scandinavian languages
From Sten's professional profile.
Colleagues at Sunstone Capital
Claus Andersson
General Partner at Sunstone Capital
Kartik Kashyap
Student Assistant at Sunstone Capital
Line Jacobsen
Management Assistant at Sunstone Capital
Merete Lundbye Møller
Venture Partner, General Counsel at Sunstone Capital
Sophie Blomgren-Hansen
Student Assistant at Sunstone Capital
Søren Lemonius
Managing General Partner at Sunstone Capital
Søren Rask Tange
Finance Director at Sunstone Capital
Frequently asked questions
- Who is Sten Verland?
- Sten Verland is a venture partner and founding partner at Sunstone Life Science Ventures who brings experience in executive management, venture capital, and pharmaceutical development. He holds a PhD in Immunology and has served as a CEO, board member, and chairman across biotech and pharmaceutical companies, with expertise in drug development, M&A, and fundraising. Verland also participates in innovation funding committees supporting early-stage life science ventures.
- Where does Sten Verland work?
- Sten Verland is Venture Partner at Sunstone Capital.
- Where did Sten Verland go to school?
- Sten Verland studied at Københavns Universitet - University of Copenhagen (Doctor of Philosophy - PhD, Immunology); Københavns Universitet - University of Copenhagen (Master of Science - MSc, Biology and Mathematics).
Same school
Also attended Københavns Universitet - University of Copenhagen97
David HelgasonUnity co-founder; Partner at TransitionJesper GromadaInvestor at Third Rock VenturesTommy AhlersFormer Danish Science Minister at Giant Ventures Global LlpClaus AnderssonGeneral Partner at Sunstone CapitalSophie Blomgren-HansenStudent Assistant at Sunstone CapitalTine LindgreenPrincipal at SEED Capital Denmark
+ 91 more
